MOESM5 of Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

  • Jr Jiun Liu (Creator)
  • Pin Yuan Chen (Contributor)
  • Shang Hung Chen (Contributor)
  • Jui Mei Chu (Contributor)
  • Chia Hung Chien (Contributor)
  • Wen-Bin Yang (Creator)
  • Wei-Lun Lo (Creator)
  • Tsung-I Hsu (Contributor)
  • Ka Yen Yang (Creator)
  • Pei Hsuan Chung (Contributor)
  • Shao Wen Chou (Creator)
  • Kwang Yu Chang (Contributor)
  • Shun Tai Yang (Creator)
  • Jian-Ying Chuang (Creator)
  • Chih Yuan Huang (Contributor)
  • Ming Sheng Liu (Creator)



Additional file 5: Figure S5. The assays of tumor-initiating cell (TIC) properties. (A) Tumor formation analysis with limiting dilution (50~1000 cells per injection) of U87-parental and TMZ-resistant (r#10) cells in subcutaneous flank area of NOD-SCID mice was performed and recorded. Tumor formation was defined as the measurement to reach 0.1â cm3 or larger. The number of tumor formation in total implanted mice was shown in the brackets. (B) The frequency of the TIC-featured population of GBM#2 (derived from another recurrent GBM patient) with or without TMZ treatment was estimated using the in vitro extreme limiting dilution assay.
Date made available2019

Cite this